Eric Rowinsky

Sporos is transforming knowledge into new hope for patients. With deep roots in Texas, connections within Texas Medical Center (TMC) and reach across the industry, the Company identifies novel disease mechanisms and strategically deploys talent, capital and access to operational resources to catalyze the development of breakthrough medicines. Sporos’ current pipeline is diversified across four entities and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease.